8/15/2019 4:35:20 PM
Mirati Therapeutics Appoints Jenny Gizzi As VP, Human Resources
7/1/2019 4:43:13 PM
Mirati Therapeutics Appointa Julie Cherrington To Board Of Directors
6/27/2019 4:21:53 PM
Mirati Therapeutics Closes Public Offering Of Common Stock
6/25/2019 8:33:54 AM
Mirati Therapeutics Prices Public Offering Of 2.10 Mln Shares At $97.00/shr
6/24/2019 4:02:35 PM
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
4/29/2019 4:12:58 PM
Mirati Therapeutics Q1 Loss/share $1.17 Vs. Loss $0.51 Year Ago
2/28/2019 4:28:26 PM
Mirati Therapeutics Q4 Loss/share $0.87 Vs. Loss $0.67 Year Ago
2/19/2019 4:18:01 PM
Mirati Therapeutics Appoints Faheem Hasnain As Chairman Of The Board
1/16/2019 8:57:07 PM
Mirati Therapeutics Prices Underwritten Public Offering Of 1.61 Mln Shares At $62.00/shr
1/16/2019 4:02:08 PM
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
1/7/2019 8:38:12 AM
Mirati Collaborates With Bristol-Myers For Phase 3 Trial In NSCLC To Evaluate Sitravatinib In Combination With Nivolumab
12/10/2018 4:21:45 PM
Mirati Therapeutics Appoints Maya Martinez-Davis To Board Of Directors
11/9/2018 8:51:51 AM
Mirati Reports Preliminary Biomarker Data From Phase 2 Clinical Trial Of Sitravatinib Combined With Nivolumab
11/9/2018 8:44:35 AM
Mirati Announces Data From Phase 2 Trial Of Mocetinostat In Combination With Durvalumab In NSCLC Patients